Navamedic ASA is a fast-growing speciality pharma company with high growth ambitions. The company is well underway with the commercialization of its osteoarthritis medicine Glucomed. Glucomed was in 2006, as the first glucosamine product, approved by European authorities for marketing as a drug in all EU countries.

In 2007 Navamedic initiated, through the acquisition of Vitaflo Scandinavia AB, an expansion of its strategy to include marketing of pharmaceutical products in selected countries. Vitaflo represents more than 40 products from 20 foreign companies in the Nordic markets. Navamedic aspires to grow both through increased geographical presence and a broader product portfolio within selected knowledge areas. On top of organic growth, the company will continue to evaluate further company and/or product acquisitions.

Navamedic ASA has been listed on the Oslo Børs (Oslo stock exchange) since 31 March, 2006.